Unregistered Sales of Equity Securities. As previously disclosed, on October 8, 2025, Turn Therapeutics Inc. (the “Company”) issued to GEM Yield Bahamas Limited a warrant (the “Warrant”) to purchase 1,192,207 shares of the Company’s common stock, par value $0.0001 per share (the “Common Stock”), representing 4% of the Company’s fully diluted outstanding shares as of such date. The Warrant has an exercise price of $5.03 per share (the “Warrant Price”), subject to certain adjustments set forth…

Regulation FD Disclosure. On August 14, 2026, Turn Therapeutics Inc. (the “Company”) entered into securities purchase agreements with certain accredited investors, consisting of existing series and seed investors of the Company (collectively, the “Investors”), pursuant to which the Company has agreed to issue and sell to the Investors, and the Investors have severally agreed to purchase, a total of 135,000 shares of the Company’s common stock, par value $0.0001 per share (the “Shares”), at a…

of this Current Report on Form 8-K and the Press Release furnished as Exhibit 99.1 hereto shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such a filing.

of this Current Report on Form 8-K and the Press Release furnished as Exhibit 99.1 hereto shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such a filing.

of this Current Report on Form 8-K and the Press Release furnished as Exhibit 99.1 hereto shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such a filing.

The securities described above will be offered and sold in reliance upon an exemption from registration provided by Section 4(a)(2) of the Securities Act of 1933, as amended (the “Securities Act”). The Equity Grant, Loans and any shares of Common Stock issuable thereunder have not been registered under the Securities Act or any state securities laws and may not be offered or sold in the United States absent registration with the U.S. Securities and Exchange Commission (the “SEC”), or an appli…

Entry into a Material Definitive Agreement. Loan Agreement On March 23, 2026 (the “Closing Date”), Turn Therapeutics Inc. (the “Company”) entered into a Loan and Security Agreement (the “Loan and Security Agreement”) and a Supplement to the Loan and Security Agreement (the “Supplement” and, together with the Loan and Security Agreement, the “Loan Agreement”), with Avenue Venture Opportunities Fund II, L.P., as administrative agent, collateral agent (in such capacities, the “Agent”) and as a l…

Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant. The disclosure set forth in

Director — Martin Dewhurst: The company appointed Martin Dewhurst as a new independent director and chair of the compensation committee.

of this Current Report on Form 8-K and the Press Release furnished as Exhibit 99.1 hereto shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such a filing.

Entry into a Material Definitive Agreement. On October 27, 2025, Turn Therapeutics, Inc. (the “Company” or “Turn”) entered into a Global Supply, Development, and License Agreement (the “Agreement”) with Medline Industries, LP (“Medline”), the world’s largest privately held manufacturer and distributor of medical-surgical products. Pursuant to the Agreement, Turn and Medline will collaborate to develop, manufacture, and commercialize professional and consumer health products that leverage Turn…

Entry into a Material Definitive Agreement On September 30, 2025 (the “Effective Time”), the Securities Exchange Commission declared effective the registration statement of Turn Therapeutics Inc., a Delaware corporation (“we,” “us,” “our” or the “Company”) on Form S-1 (File No. 333-289972), as amended (the “Registration Statement”) in connection with the direct listing of its common stock, par value $0.0001 per share (“Common Stock”), on the Nasdaq Global Market (the “Direct Listing”), pursua…

Director — Arthur Golden and Dr. Kent Kester: Two new independent directors were appointed to the board in connection with a direct listing.

Material Modification to Rights of Security Holders. The information set forth under